The Axe is going to drop

Quote






This place has become a real junk. just waiting to see it go down, no one in the company respects others, there are violations all over, not only HR but other compliance violations everywhere in the company, but no once cares. Sr mgt only cares abt their $$$$ and not people..
 






Anonymous said:
This place has become a real junk. just waiting to see it go down, no one in the company respects others, there are violations all over, not only HR but other compliance violations everywhere in the company, but no once cares. Sr mgt only cares abt their $$$$ and not people..
Click to expand...

Linkedin is ablaze with updates from Caris executives....perhaps they are looking too??
 












And now it is even a bigger laughingstock. High priced test that cannot be sold. Constantly changing technology with associated losses based on poor personnel choices and a another female at the helm with hair brained ideas, a bloated and false sense of self and a new VP of Sales who was and idiot. then there is the old guard from HR who does nothing and a visionless CFO. All in all a great company that is a laughing stock. Nice. I am so proud.
 












the fact is we are selling sufficient tests. however, no matter how many tests we sell it is irrelevant. DH is not really behind molecular profiling. he wants crappysomes and our senior management is preparing to manage that including Elle Bee who is the biggest liar and cover up artist. Blames all others for her mismanagement of all projects. do not trust the Elle Bee.
 












Not sure axe is dropping. DH preparing sale of MP but is dumping large amounts of investment into the company so that it looks stable and to keep it going so he can then sell it off. I think we are okay for about another year or two to be honest. I believe that the main thing is to watch out for the back stabbing and plotting in specific area of the company since those who manage those areas lack integrity. I think that we can be confident that as long as we sell we are safe in particular if the profit from the sale and insurance reimbursement goes shores up our profit margin. However, I would suggest being very careful of a couple VPs i.e. TG who is a snake and not to be trusted and then Elle Bee who is a terrible manager and a lying sack of shit. There are a couple of SDs that need watching namely JF as that one is out for glory and is a nasty bitch for sure. Jay Eff is protected by Queen Elle Bee so be very careful. Those are the mine fields I can think of right now. However, T.S. is weak and JM is a calculator dressed in human clothes.Being aware of all the players and their agendas will keep us safe. DH of course is complete mistake for a human. He lies. Let's keep our wits about us.
 






Caris will be around longer than a year or two. The axe was predicted to drop two years ago, and yet the company still moves ahead, maybe with a limp, but it moves. Leadership seems to be wonky, but they are still there and plugging away. Many of them could go other places and they are still there ... When the JMs and TSs leave ... then you know it's over.
 






you are probably correct. company doing better than expected I think. Too bad people with low integrity and lack of ethics still here. PP is excellent. Should have come in 2 years ago. Elle Bee is not to be trusted and lacks integrity. Elle Bee lies and blames others for Elle Bee actions. Do not trust Elle Bee. I know I am watching my back at all times. However, Elle Bee has good company with the other crappy managers and VPs at Caris.
 






yes Elle Bee or whatever code name is a real piece of work. Comes off nicey nice in meetings and all about women and trust and is actually a sack of shit liar and lacks ethics and integrity. Do not trust Elle Bee or TS (they are fucking anyway)
 






This is interesting: Read below

Please note that Caris is not the selected molecular profiling company for US Oncology. Wow. Does Elle Bee know her shit or what? hahahahahahaha Thank God we are making money anyway.


The US Oncology Network Selects med fusion and Foundation Medicine to Optimize Molecular Diagnostic Testing and Enhance the Delivery of High-Quality, Precision Medicine




THE WOODLANDS, Texas--(BUSINESS WIRE)--Physicians in The US Oncology Network, supported by McKesson Specialty Health, announced today the selection of med fusion and Foundation Medicine as their preferred diagnostic labs. This new relationship is expected to advance the delivery of high-quality, precision medicine and the appropriate use of molecular diagnostics, supporting The US Oncology Network in continuing to deliver high-quality, cost-effective cancer care.


“We’re very excited about the selection of med fusion and Foundation Medicine to help us with our precision medicine initiative. They are both leaders in molecular testing and will offer physicians in The US Oncology Network a broad array of testing services”
.
“We’re very excited about the selection of med fusion and Foundation Medicine to help us with our precision medicine initiative. They are both leaders in molecular testing and will offer physicians in The US Oncology Network a broad array of testing services,” says Marcus Neubauer, MD, medical director of Oncology Services for McKesson Specialty Health and The US Oncology Network.

The US Oncology Network is one of the nation’s largest networks of community based oncology physicians and integrated cancer care practices. Through a physician-led request for proposal (RFP) process, The Network selected med fusion and Foundation Medicine from a broad field of candidates.

Located in Lewisville, Texas, med fusion was selected for its logistical capabilities and broad clinical testing menu and will serve as the diagnostic gateway for The US Oncology Network.

Foundation Medicine, a molecular information company, was selected for its FoundationOne™ test, which offers a fully informative genomic profile useful in many cancer types and clinical scenarios. Med fusion and Foundation Medicine will also contribute guidance and educational support around genomics-based oncology. Working with both companies allows physicians in The US Oncology Network to meet the needs of patients with a variety of types and stages of cancer.

“Molecular diagnostics are becoming increasingly important in oncology care and it’s imperative for physicians to have the support they need to order the right test at the right time,” says Dr. Neubauer. “The US Oncology Network empowers its affiliated physicians to collaborate on important topics like precision medicine, molecular diagnostics and evidence-based treatments so that all physicians in The Network have easy access to the tools, resources and support necessary to provide patients with high-quality cancer care.”

By working with med fusion and Foundation Medicine, physicians in The US Oncology Network will have a simplified technology solution that will streamline ordering and data collection, provide access to and guidance about use of the most advanced cancer testing, and support US Oncology Research clinical trials.

“There is an onslaught of new tumor profile tests from clinical labs. We would like to give physicians in The Network guidance on which tests to order for which patients and help payers understand how these tests will improve patient care and potentially reduce overall cost of care,” says Neubauer.

“Clinical trials are a critical part of patient care, and molecular data is now often required to enroll patients in trials,” says Steve Jones, MD, medical director for US Oncology Research, a nationwide network of physician investigators supported by McKesson Specialty Health. “This initiative will improve our ability to identify and enroll patients in these targeted trials.”

Precision Medicine—the tailoring of medical treatment to the genetic characteristics of each patient’s tumor—is a priority for The US Oncology Network as more therapies become targeted to specific genetic mutations. Tumor profiles provide varying amounts of genomic information on a patient’s tumor. Many companies, both large and small, are offering these tests and prevalence is expected to grow.

“A great deal of variability exists today. As a network of cancer care doctors dedicated to identifying and driving solutions for the delivery of quality cancer care, we, in The US Oncology Network, are determined to understand and provide guidance as to which tests are necessary to determine which treatment is most effective for which patients,” says Neubauer.

In addition to its molecular diagnostic initiative, The US Oncology Network is driving several other precision medicine related initiatives including the development of diagnostic pathways, which will be critical as the complexity of diagnostics grows. Testing and implementing diagnostic pathways is another way The US Oncology Network will help clinicians address variations in treatment to help improve care, while having a positive impact on oncology cost trends.

About The US Oncology Network

The US Oncology Network is the nation’s largest network of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, precise evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of regional payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system. For more information, visit www.usoncology.com.

About McKesson Specialty Health

McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. For more information, visit www.mckessonspecialtyhealth.com.

About US Oncology Research

Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves approximately 80 research sites and nearly 225 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 55,000 patients in over 1,200 trials since inception in 1992 and have contributed to the development of 46 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.


Contacts


The US Oncology Network
Jennifer Horspool, 949-933-4300 or 424-247-7858
Jennifer.Horspool@usoncology.com


Recent Stories

View Press Release.
US Oncology Research, The US Oncology Network and McKesson Specialty Health Affiliated Investigators Participate in 90 Studies Featured at ASCO 2013

May 28, 2013



THE WOODLANDS, Texas--(BUSINESS WIRE)--More than 85 investigators affiliated with US Oncology Research, The US Oncology Network and McKesson Specialty Health participated in 90 studies that will be... more »
 






Why is Caris not being selected Elle Bee's fault. Elle Bee is a liar and lacks integrity, ethics, honesty morals and is two faced and back stabbing and sleeping her way to the top with TS. Elle Bee cannot be trusted under any circumstances as Elle Bee will do and say anything to stay on top of the pile. However, Elle Bee cannot be held responsible for Foundation being chosen as the preferred provider. That is mean
 
























Anonymous said:
This is interesting: Read below

Please note that Caris is not the selected molecular profiling company for US Oncology. Wow. Does Elle Bee know her shit or what? hahahahahahaha Thank God we are making money anyway.


The US Oncology Network Selects med fusion and Foundation Medicine to Optimize Molecular Diagnostic Testing and Enhance the Delivery of High-Quality, Precision Medicine




THE WOODLANDS, Texas--(BUSINESS WIRE)--Physicians in The US Oncology Network, supported by McKesson Specialty Health, announced today the selection of med fusion and Foundation Medicine as their preferred diagnostic labs. This new relationship is expected to advance the delivery of high-quality, precision medicine and the appropriate use of molecular diagnostics, supporting The US Oncology Network in continuing to deliver high-quality, cost-effective cancer care.


“We’re very excited about the selection of med fusion and Foundation Medicine to help us with our precision medicine initiative. They are both leaders in molecular testing and will offer physicians in The US Oncology Network a broad array of testing services”
.
“We’re very excited about the selection of med fusion and Foundation Medicine to help us with our precision medicine initiative. They are both leaders in molecular testing and will offer physicians in The US Oncology Network a broad array of testing services,” says Marcus Neubauer, MD, medical director of Oncology Services for McKesson Specialty Health and The US Oncology Network.

The US Oncology Network is one of the nation’s largest networks of community based oncology physicians and integrated cancer care practices. Through a physician-led request for proposal (RFP) process, The Network selected med fusion and Foundation Medicine from a broad field of candidates.

Located in Lewisville, Texas, med fusion was selected for its logistical capabilities and broad clinical testing menu and will serve as the diagnostic gateway for The US Oncology Network.

Foundation Medicine, a molecular information company, was selected for its FoundationOne™ test, which offers a fully informative genomic profile useful in many cancer types and clinical scenarios. Med fusion and Foundation Medicine will also contribute guidance and educational support around genomics-based oncology. Working with both companies allows physicians in The US Oncology Network to meet the needs of patients with a variety of types and stages of cancer.

“Molecular diagnostics are becoming increasingly important in oncology care and it’s imperative for physicians to have the support they need to order the right test at the right time,” says Dr. Neubauer. “The US Oncology Network empowers its affiliated physicians to collaborate on important topics like precision medicine, molecular diagnostics and evidence-based treatments so that all physicians in The Network have easy access to the tools, resources and support necessary to provide patients with high-quality cancer care.”

By working with med fusion and Foundation Medicine, physicians in The US Oncology Network will have a simplified technology solution that will streamline ordering and data collection, provide access to and guidance about use of the most advanced cancer testing, and support US Oncology Research clinical trials.

“There is an onslaught of new tumor profile tests from clinical labs. We would like to give physicians in The Network guidance on which tests to order for which patients and help payers understand how these tests will improve patient care and potentially reduce overall cost of care,” says Neubauer.

“Clinical trials are a critical part of patient care, and molecular data is now often required to enroll patients in trials,” says Steve Jones, MD, medical director for US Oncology Research, a nationwide network of physician investigators supported by McKesson Specialty Health. “This initiative will improve our ability to identify and enroll patients in these targeted trials.”

Precision Medicine—the tailoring of medical treatment to the genetic characteristics of each patient’s tumor—is a priority for The US Oncology Network as more therapies become targeted to specific genetic mutations. Tumor profiles provide varying amounts of genomic information on a patient’s tumor. Many companies, both large and small, are offering these tests and prevalence is expected to grow.

“A great deal of variability exists today. As a network of cancer care doctors dedicated to identifying and driving solutions for the delivery of quality cancer care, we, in The US Oncology Network, are determined to understand and provide guidance as to which tests are necessary to determine which treatment is most effective for which patients,” says Neubauer.

In addition to its molecular diagnostic initiative, The US Oncology Network is driving several other precision medicine related initiatives including the development of diagnostic pathways, which will be critical as the complexity of diagnostics grows. Testing and implementing diagnostic pathways is another way The US Oncology Network will help clinicians address variations in treatment to help improve care, while having a positive impact on oncology cost trends.

About The US Oncology Network

The US Oncology Network is the nation’s largest network of integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care. A physician-led organization, The US Oncology Network unites like-minded physicians and clinicians around a common vision of improving patient outcomes and quality of life. Leveraging healthcare information technology, shared best practices, precise evidence-based guidelines and quality measurements, physicians within The US Oncology Network are pioneering new ways to achieve this vision. The US Oncology Network is committed to strengthening patient access to integrated care in local communities across the nation, including collaboration with a variety of regional payers, hospitals and academic institutions. The US Oncology Network is supported by McKesson Specialty Health, a division of McKesson Corporation focused on empowering a vibrant and sustainable community patient care delivery system. For more information, visit www.usoncology.com.

About McKesson Specialty Health

McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system by helping community practices advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we focus on improving the financial health of our customers so they may provide the best care to their patients. For more information, visit www.mckessonspecialtyhealth.com.

About US Oncology Research

Supported by McKesson Specialty Health and The US Oncology Network, US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in Phase I through Phase IV oncology clinical trials. US Oncology Research serves approximately 80 research sites and nearly 225 locations managing about 225 active trials at any given time. Physicians in the research network have enrolled more than 55,000 patients in over 1,200 trials since inception in 1992 and have contributed to the development of 46 cancer therapies approved by the FDA. For more information call (800) 482-6700, option 4 or visit www.usoncology.com/oncologists.


Contacts


The US Oncology Network
Jennifer Horspool, 949-933-4300 or 424-247-7858
Jennifer.Horspool@usoncology.com


Recent Stories

View Press Release.
US Oncology Research, The US Oncology Network and McKesson Specialty Health Affiliated Investigators Participate in 90 Studies Featured at ASCO 2013

May 28, 2013



THE WOODLANDS, Texas--(BUSINESS WIRE)--More than 85 investigators affiliated with US Oncology Research, The US Oncology Network and McKesson Specialty Health participated in 90 studies that will be... more »
Click to expand...

YES , BUT CMS WILL NOT AWARD A CPT CODE FOR FOUNDATION, THEY ESSENTIALLY DENIED INCREASED REIMBURSEMENT. FOUNDATION IS GOING TO HAVE TO BILL LIKE EVERYONE ELSE!
 












Well, I am more surprised that the Queen of liars and back stabbing behavior has not imploded. You can only screw people, lie, and without conscience for a short while before people catch on. Elle Bee your team is afraid of you because you cannot be trusted. We do not trust anything you say or do and all the talk about team work is really self-promotion for your next gig. Also, sleeping with senior management is an age old cliché. Maybe you should have been working during the Mad Men era and been a secretary.
 






Top Bottom
Back
Quote